Advanced

Cell transplantation in Parkinson's disease: how can we make it work?

Winkler, C; Kirik, Deniz LU and Björklund, Anders LU (2005) In Trends in Neurosciences 28(2). p.86-92
Abstract
Previous open-label clinical trials have provided proof of principle that intrastriatal transplants of fetal dopaminergic neurons can induce substantial and long-lasting functional benefits in patients with Parkinson's disease. However, in two recent NIH-sponsored double-blind trials, functional improvements were only marginal and the primary endpoints were not met. Severe off-phase dyskinesias were observed in a significant proportion of the transplanted patients, raising doubts about the viability of the cell-transplantation approach. Here, we discuss the problems raised by the NIH-sponsored trials and point to several shortcomings that might explain the overall poor outcome, and we identify several crucial issues that remain to be... (More)
Previous open-label clinical trials have provided proof of principle that intrastriatal transplants of fetal dopaminergic neurons can induce substantial and long-lasting functional benefits in patients with Parkinson's disease. However, in two recent NIH-sponsored double-blind trials, functional improvements were only marginal and the primary endpoints were not met. Severe off-phase dyskinesias were observed in a significant proportion of the transplanted patients, raising doubts about the viability of the cell-transplantation approach. Here, we discuss the problems raised by the NIH-sponsored trials and point to several shortcomings that might explain the overall poor outcome, and we identify several crucial issues that remain to be resolved to develop cell replacement into an effective and safe therapy. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Trends in Neurosciences
volume
28
issue
2
pages
86 - 92
publisher
Elsevier
external identifiers
  • wos:000227225600008
  • scopus:13144259693
ISSN
1878-108X
DOI
10.1016/j.tins.2004.12.006
language
English
LU publication?
yes
id
a7bdc15d-b15f-4273-9a7d-22a0b2f34de2 (old id 251028)
date added to LUP
2007-08-08 11:15:10
date last changed
2017-11-05 04:37:35
@misc{a7bdc15d-b15f-4273-9a7d-22a0b2f34de2,
  abstract     = {Previous open-label clinical trials have provided proof of principle that intrastriatal transplants of fetal dopaminergic neurons can induce substantial and long-lasting functional benefits in patients with Parkinson's disease. However, in two recent NIH-sponsored double-blind trials, functional improvements were only marginal and the primary endpoints were not met. Severe off-phase dyskinesias were observed in a significant proportion of the transplanted patients, raising doubts about the viability of the cell-transplantation approach. Here, we discuss the problems raised by the NIH-sponsored trials and point to several shortcomings that might explain the overall poor outcome, and we identify several crucial issues that remain to be resolved to develop cell replacement into an effective and safe therapy.},
  author       = {Winkler, C and Kirik, Deniz and Björklund, Anders},
  issn         = {1878-108X},
  language     = {eng},
  number       = {2},
  pages        = {86--92},
  publisher    = {Elsevier},
  series       = {Trends in Neurosciences},
  title        = {Cell transplantation in Parkinson's disease: how can we make it work?},
  url          = {http://dx.doi.org/10.1016/j.tins.2004.12.006},
  volume       = {28},
  year         = {2005},
}